[低估纯辐射痕:癌症中心的回顾性评估]
Andréa Musard1, Marie-Martine Padéano1, Nathalie Méjean1
1Centre Georges-François Leclerc, 1, rue Professeur-Marion, BP 77980, 21079 Dijon cedex, France.
Gynecologie, obstetrique, fertilite & senologie
|March 6, 2025
概括
放射性痕 (RS) 是良性乳腺病变,可以模仿癌症. 这项研究发现,放射性痕的低估率为21.4%,强调需要仔细诊断和多学科讨论.
科学领域:
- 乳房成像和病理学
- 手术瘤学手术瘤学
- 放射学 放射学是一门学科.
背景情况:
- 放射性痕 (RS) 是良性乳腺病变,具有可类似恶性瘤的成像特征.
- 从历史上看,由于低估风险,手术切除是RS的标准,但目前的指导方针允许监测.
- 评估低估风险对于指导管理决策至关重要.
研究的目的:
- 评估活检中放射性痕 (RS) 的低估率.
- 为了确定与RS低估相关的潜在风险因素.
- 在随访期间确定RS患者乳腺癌发病率.
主要方法:
- 在单个癌症中心 (2000-2015) 进行了回顾性观察性研究.
- 对116次活检的分析,最初被诊断为无异型性无辐射痕.
- 对切除病理和患者随访数据的审查.
主要成果:
- 辐射痕的整体低估率为21.4%.
- 观察到2.9%的低估率为瘤 (在位或侵入性).
- 没有发现低估的预测因素;16.7%的随访患者患有乳腺癌.
结论:
- 辐射痕表现出明显的低估率,需要仔细的病理审查.
- 没有确定的预测性风险因素强调了个性化评估的重要性.
- 多学科团队讨论对于管理辐射痕和指导监视或切除决策至关重要.
相关概念视频
02:57Targeted Cancer Therapies
7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.0K
01:21Cancer Survival Analysis
863
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
863